Drug Profile
Centhaquine - Midwestern University/Pharmazz
Alternative Names: Centhaquin - Midwestern University/Pharmazz; Centhaquine citrate; Lyfaquin; PMZ 2010; PMZ-2010 citrateLatest Information Update: 27 Mar 2024
Price :
$50
*
At a glance
- Originator Midwestern University; Pharmazz
- Developer Pharmazz
- Class Analgesics; Antihaemorrhagics; Antihypertensives; Cardiovascular therapies; Piperazines; Quinolines; Small molecules
- Mechanism of Action Alpha 1 adrenergic receptor antagonists; Alpha 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypovolaemic shock
- Phase III Stroke
- Phase II Septic shock
- Phase I Acute kidney injury; SARS-CoV-2 acute respiratory disease
- No development reported Heart arrest; Postoperative pain
Most Recent Events
- 22 Mar 2024 Dr. Reddy's Laboratories Limited in-licenses Centhaquine from Pharmazz
- 22 Jun 2023 Pharmazz plans phase III clinical trial in Hypovolaemic shock (In adults, In elderly) in October 2023 (IV) (NCT05251181)
- 28 Aug 2022 No recent reports of development identified for phase-I development in Heart-arrest in USA (IV, Infusion)